KLOW is a peptide combination (GHK-Cu / TB-500 / BPC-157 / KPV) commonly explored in provider-directed recovery and regenerative wellness programs. It is frequently considered in programs focused on advanced healing, anti-inflammatory support, skin rejuvenation, and recovery, and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
KLOW is commonly explored by healthcare providers as part of recovery and regenerative wellness programs. Areas of clinical interest may include:
Advanced Healing — Often considered in provider-directed programs focused on advanced healing and tissue response.
Anti-Inflammatory Support — May be explored within programs designed to support inflammatory wellness and recovery.
Skin Rejuvenation — May be considered for patients whose goals include skin health, appearance, and regenerative wellness.
Recovery Support — May be explored within programs focused on recovery following strenuous physical activity or musculoskeletal stress.
KLOW should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
KLOW combines a copper-binding peptide (GHK-Cu), a thymosin beta-4-based peptide (TB-500), a gastric-juice-derived peptide (BPC-157), and a melanocortin-derived fragment (KPV). Preclinical research has investigated several biological pathways that may help explain the interest in this combination within recovery and regenerative medicine.
Areas being studied include:
Tissue Repair and Remodeling — Components of KLOW have been studied for their association with cellular processes involved in tissue repair and remodeling.
Collagen and Extracellular Matrix — Research has investigated potential effects on collagen synthesis and extracellular matrix components relevant to skin and connective tissue.
Angiogenesis and Blood-Vessel Signaling — Components have been examined for interactions with pathways involved in new blood-vessel formation and tissue response.
Inflammatory Signaling — Preclinical studies have investigated potential effects on biological pathways involved in inflammatory responses.
Evidence for KLOW remains primarily preclinical. These mechanisms have not established clinical efficacy or safety in humans, and KLOW is not FDA-approved.
Clinical Information
Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering KLOW for a patient.
Include these considerations:
Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.
Use Within Approved and Appropriate Context — KLOW should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.
Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors throughout the course of use.
Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Low / Starting Dose | 0.25 mg once daily |
| Standard Dose | 0.50 mg once daily |
| High Dose | 0.50 mg once daily |
| Frequency | Daily |
| Dose Unit | mg/day |
| Administrations Per Week | 7 |
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify KLOW as a product for a healthcare professional to explore when the described patient goals involve advanced healing, anti-inflammatory support, skin rejuvenation, or recovery.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.